Examples of using To insufficient data in English and their translations into Swedish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
-
Political
Tamiflu is not recommended for use in children less than one year of age due to insufficient data on safety and efficacy see section 5.3.
Tandemact is not recommended for use in patients below age 18 due to insufficient data on safety and efficacy.
Tyverb is not recommended for use in paediatrics due to insufficient data on safety and efficacy.
Children(age below 12 years) Xolair is not recommended for use in children below age 12 due to insufficient data on safety and efficacy.
Paediatric population(< 18 years) Gemcitabine is not recommended for use in children under 18 years of age due to insufficient data on safety and efficacy.
Revatio solution for injection is not recommended for use in children below 18 years due to insufficient data on safety and efficacy.
adolescents below 18 years of age due to insufficient data on safety and efficacy.
adolescents below 18 years of age due to insufficient data on safety and efficacy.
TachoSil is not recommended for use in children below age 18 years due to insufficient data on safety and efficacy.
Tasmar is not recommended for use in children below the age of 18 due to insufficient data on safety or efficacy.
Paediatric patients CHAMPIX is not recommended for use in children or adolescents below 18 years of age due to insufficient data on safety and efficacy see section 5.2.
adolescents below age 18 due to insufficient data on safety and efficacy.
adolescents below 18 years of age due to insufficient data on safety and efficacy.
Aloxi is not recommended for use in children below age 18 due to insufficient data.
Children and adolescents ECALTA is not recommended for use in children below 18 due to insufficient data on safety and efficacy see section 5.2.
adolescents under age 18 due to insufficient data on safety and efficacy.
Fuzeon is not recommended for use in children below age 6 due to insufficient data on safety and efficacy see section 5.2.
Paediatric use Herceptin is not recommended for use in children below 18 due to insufficient data on safety and efficacy.
IONSYS is not recommended for use in children below age 18 years due to insufficient data on safety and efficacy.
Kaletra is not recommended for use in children below 2 years of age due to insufficient data on safety and efficacy see section 5.1.